← Reviews
Jul 30, 2026

Autoprobiotic supplements attenuate obesity and improve gut microbiota and metabolism in metabolic syndrome: a pilot trial

Autologous Enterococcus faecium and E. hirae supplementation reduced HbA1c and triglycerides compared to control in metabolic syndrome patients 28 days after a 20-day intervention.

Evidence levelCObservational / small clinical study
Study typerct
Sample50
Effect directionFavorable
CertaintyLow
Clinical applicabilityLow
Overinterpretation risk1/5 · Low
PICO
Population
Intervention
Comparator
Outcome

What the study showed

The autoprobiotic group showed reductions in blood glucose, HbA1c, and partial lipid profile normalization, along with gut microbiota changes assessed by qPCR and 16S rRNA sequencing. Intergroup comparison at day 28 revealed lower HbA1c and triglyceride concentrations in the experimental group. Taxonomic shifts included decreased Bacteroides fragilis group, Streptococcus spp., and Ruminococcus spp. in the autoprobiotic arm.

How it was done

Randomized pilot clinical trial with 50 metabolic syndrome patients (n=26 autoprobiotic, n=24 control) over 20 days; outcomes assessed at days 14 and 28 post-intervention using anthropometric, biochemical, and microbiome analyses.

Risk of bias

Small sample size (n=50) and pilot design substantially limit statistical power and generalizability. The abstract does not specify blinding, randomization quality, or control for dietary and lifestyle confounders during follow-up.

Interpretation limit

What this study does NOT prove

This study does not prove that autoprobiotics cause durable remission or control of metabolic syndrome, nor that they outperform dietary interventions or conventional probiotics.

In clinical practice

Preliminary findings do not support changes in clinical practice. Autoprobiotic approaches require validation in adequately powered, rigorous trials before any recommendation can be made.

Limitations

Small sample size (n=50) and pilot design substantially limit statistical power and generalizability. The abstract does not specify blinding, randomization quality, or control for dietary and lifestyle confounders during follow-up.

Technical appendix

Version history

  • 1.0 · 2026-07-30 — Auto-generated under Evidence Standard v1.0
Source: DOI 10.3390/nu18142324 · 2026

Paid access: structured summary from public metadata; consult the original study at the source.

Microbiota Weekly

The week in microbiota evidence, in your language. Structured summaries, traceable to the source.